Nature:英国万人基因组计划揭示罕见突变与人类疾病关系

2015-09-21 佚名 生物谷

近日,著名国际学术期刊Nature刊登了迄今为止最大的人群基因组测序研究,而关于这些数据的来源和用途也同一时间发表在了Nature, Nature Genetics, Bioinformatics以及Nature Communication等Nature系列杂志上。罕见基因突变是DNA中携带的遗传变化,而在一个人群中携带这种突变的人相对较少。英国的万人研究就是为了探究罕见遗传突变与人类疾病和疾病风

近日,著名国际学术期刊Nature刊登了迄今为止最大的人群基因组测序研究,而关于这些数据的来源和用途也同一时间发表在了Nature, Nature Genetics, Bioinformatics以及Nature Communication等Nature系列杂志上。

罕见基因突变是DNA中携带的遗传变化,而在一个人群中携带这种突变的人相对较少。英国的万人研究就是为了探究罕见遗传突变与人类疾病和疾病风险因子之间的关系而设计的。

研究人员指出,这项研究为描述罕见遗传突变在人类疾病发展中发挥的作用做出了重要贡献,我们可以从中了解到对几***进行测序的重要意义,这为未来研究更大样本量的复杂疾病提供了重要基础。

这项研究包含了接近10,000名参与者,其中既有健康人也有受到疾病影响的病人,其中包括非常罕见的家族遗传性疾病,以及一些更加常见的疾病,如自闭症,精神分裂症和肥胖。在健康人群中,研究人员对64种不同的生物医学风险因子,如血压和胆固醇水平进行了研究。通过对参与者的DNA序列进行分析,这一计划获得了大量关于罕见遗传突变与人类疾病之间的信息,同时还发现了一些新的遗传突变以及一些可能导致疾病发生的风险基因。

研究人员这样说道:"英国万人计划增加了人们对深入探索遗传奥秘的决心,同时还使人们有机会了解英国人群基因组中存在的更大密度的遗传突变,能够帮助我们重新认识遗传效应对表型特征的影响。"

一系列发表在国际学术期刊上的文章已经证明了这一计划对遗传学新发现具有重要价值。

原文出处:

The UK10K project identifies rare variants in health and disease. nature. 2015


版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (6)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1880818, encodeId=2e5a188081807, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Sun Mar 27 03:16:00 CST 2016, time=2016-03-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1952527, encodeId=2205195252e49, content=<a href='/topic/show?id=693f4185542' target=_blank style='color:#2F92EE;'>#基因组计划#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=41855, encryptionId=693f4185542, topicName=基因组计划)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=bf1b289, createdName=villahu, createdTime=Sat Apr 30 05:16:00 CST 2016, time=2016-04-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1467101, encodeId=8894146e10162, content=<a href='/topic/show?id=ef32e9539e8' target=_blank style='color:#2F92EE;'>#罕见#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79539, encryptionId=ef32e9539e8, topicName=罕见)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=29f36868190, createdName=syscxl, createdTime=Wed Sep 23 02:16:00 CST 2015, time=2015-09-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=37121, encodeId=6f353e121f6, content=不错的视角,长见识了, beContent=null, objectType=article, channel=null, level=null, likeNumber=119, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e73d1605484, createdName=he408015781, createdTime=Mon Sep 21 21:19:00 CST 2015, time=2015-09-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=37122, encodeId=9c143e122ef, content=不错的视角,长见识了, beContent=null, objectType=article, channel=null, level=null, likeNumber=158, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e73d1605484, createdName=he408015781, createdTime=Mon Sep 21 21:19:00 CST 2015, time=2015-09-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=37123, encodeId=13f23e123da, content=不错的视角,长见识了, beContent=null, objectType=article, channel=null, level=null, likeNumber=105, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e73d1605484, createdName=he408015781, createdTime=Mon Sep 21 21:19:00 CST 2015, time=2015-09-21, status=1, ipAttribution=)]
    2016-03-27 liye789132251
  2. [GetPortalCommentsPageByObjectIdResponse(id=1880818, encodeId=2e5a188081807, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Sun Mar 27 03:16:00 CST 2016, time=2016-03-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1952527, encodeId=2205195252e49, content=<a href='/topic/show?id=693f4185542' target=_blank style='color:#2F92EE;'>#基因组计划#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=41855, encryptionId=693f4185542, topicName=基因组计划)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=bf1b289, createdName=villahu, createdTime=Sat Apr 30 05:16:00 CST 2016, time=2016-04-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1467101, encodeId=8894146e10162, content=<a href='/topic/show?id=ef32e9539e8' target=_blank style='color:#2F92EE;'>#罕见#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79539, encryptionId=ef32e9539e8, topicName=罕见)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=29f36868190, createdName=syscxl, createdTime=Wed Sep 23 02:16:00 CST 2015, time=2015-09-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=37121, encodeId=6f353e121f6, content=不错的视角,长见识了, beContent=null, objectType=article, channel=null, level=null, likeNumber=119, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e73d1605484, createdName=he408015781, createdTime=Mon Sep 21 21:19:00 CST 2015, time=2015-09-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=37122, encodeId=9c143e122ef, content=不错的视角,长见识了, beContent=null, objectType=article, channel=null, level=null, likeNumber=158, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e73d1605484, createdName=he408015781, createdTime=Mon Sep 21 21:19:00 CST 2015, time=2015-09-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=37123, encodeId=13f23e123da, content=不错的视角,长见识了, beContent=null, objectType=article, channel=null, level=null, likeNumber=105, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e73d1605484, createdName=he408015781, createdTime=Mon Sep 21 21:19:00 CST 2015, time=2015-09-21, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1880818, encodeId=2e5a188081807, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Sun Mar 27 03:16:00 CST 2016, time=2016-03-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1952527, encodeId=2205195252e49, content=<a href='/topic/show?id=693f4185542' target=_blank style='color:#2F92EE;'>#基因组计划#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=41855, encryptionId=693f4185542, topicName=基因组计划)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=bf1b289, createdName=villahu, createdTime=Sat Apr 30 05:16:00 CST 2016, time=2016-04-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1467101, encodeId=8894146e10162, content=<a href='/topic/show?id=ef32e9539e8' target=_blank style='color:#2F92EE;'>#罕见#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79539, encryptionId=ef32e9539e8, topicName=罕见)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=29f36868190, createdName=syscxl, createdTime=Wed Sep 23 02:16:00 CST 2015, time=2015-09-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=37121, encodeId=6f353e121f6, content=不错的视角,长见识了, beContent=null, objectType=article, channel=null, level=null, likeNumber=119, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e73d1605484, createdName=he408015781, createdTime=Mon Sep 21 21:19:00 CST 2015, time=2015-09-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=37122, encodeId=9c143e122ef, content=不错的视角,长见识了, beContent=null, objectType=article, channel=null, level=null, likeNumber=158, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e73d1605484, createdName=he408015781, createdTime=Mon Sep 21 21:19:00 CST 2015, time=2015-09-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=37123, encodeId=13f23e123da, content=不错的视角,长见识了, beContent=null, objectType=article, channel=null, level=null, likeNumber=105, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e73d1605484, createdName=he408015781, createdTime=Mon Sep 21 21:19:00 CST 2015, time=2015-09-21, status=1, ipAttribution=)]
    2015-09-23 syscxl
  4. [GetPortalCommentsPageByObjectIdResponse(id=1880818, encodeId=2e5a188081807, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Sun Mar 27 03:16:00 CST 2016, time=2016-03-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1952527, encodeId=2205195252e49, content=<a href='/topic/show?id=693f4185542' target=_blank style='color:#2F92EE;'>#基因组计划#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=41855, encryptionId=693f4185542, topicName=基因组计划)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=bf1b289, createdName=villahu, createdTime=Sat Apr 30 05:16:00 CST 2016, time=2016-04-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1467101, encodeId=8894146e10162, content=<a href='/topic/show?id=ef32e9539e8' target=_blank style='color:#2F92EE;'>#罕见#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79539, encryptionId=ef32e9539e8, topicName=罕见)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=29f36868190, createdName=syscxl, createdTime=Wed Sep 23 02:16:00 CST 2015, time=2015-09-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=37121, encodeId=6f353e121f6, content=不错的视角,长见识了, beContent=null, objectType=article, channel=null, level=null, likeNumber=119, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e73d1605484, createdName=he408015781, createdTime=Mon Sep 21 21:19:00 CST 2015, time=2015-09-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=37122, encodeId=9c143e122ef, content=不错的视角,长见识了, beContent=null, objectType=article, channel=null, level=null, likeNumber=158, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e73d1605484, createdName=he408015781, createdTime=Mon Sep 21 21:19:00 CST 2015, time=2015-09-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=37123, encodeId=13f23e123da, content=不错的视角,长见识了, beContent=null, objectType=article, channel=null, level=null, likeNumber=105, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e73d1605484, createdName=he408015781, createdTime=Mon Sep 21 21:19:00 CST 2015, time=2015-09-21, status=1, ipAttribution=)]
    2015-09-21 he408015781

    不错的视角,长见识了

    0

  5. [GetPortalCommentsPageByObjectIdResponse(id=1880818, encodeId=2e5a188081807, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Sun Mar 27 03:16:00 CST 2016, time=2016-03-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1952527, encodeId=2205195252e49, content=<a href='/topic/show?id=693f4185542' target=_blank style='color:#2F92EE;'>#基因组计划#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=41855, encryptionId=693f4185542, topicName=基因组计划)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=bf1b289, createdName=villahu, createdTime=Sat Apr 30 05:16:00 CST 2016, time=2016-04-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1467101, encodeId=8894146e10162, content=<a href='/topic/show?id=ef32e9539e8' target=_blank style='color:#2F92EE;'>#罕见#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79539, encryptionId=ef32e9539e8, topicName=罕见)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=29f36868190, createdName=syscxl, createdTime=Wed Sep 23 02:16:00 CST 2015, time=2015-09-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=37121, encodeId=6f353e121f6, content=不错的视角,长见识了, beContent=null, objectType=article, channel=null, level=null, likeNumber=119, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e73d1605484, createdName=he408015781, createdTime=Mon Sep 21 21:19:00 CST 2015, time=2015-09-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=37122, encodeId=9c143e122ef, content=不错的视角,长见识了, beContent=null, objectType=article, channel=null, level=null, likeNumber=158, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e73d1605484, createdName=he408015781, createdTime=Mon Sep 21 21:19:00 CST 2015, time=2015-09-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=37123, encodeId=13f23e123da, content=不错的视角,长见识了, beContent=null, objectType=article, channel=null, level=null, likeNumber=105, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e73d1605484, createdName=he408015781, createdTime=Mon Sep 21 21:19:00 CST 2015, time=2015-09-21, status=1, ipAttribution=)]
    2015-09-21 he408015781

    不错的视角,长见识了

    0

  6. [GetPortalCommentsPageByObjectIdResponse(id=1880818, encodeId=2e5a188081807, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Sun Mar 27 03:16:00 CST 2016, time=2016-03-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1952527, encodeId=2205195252e49, content=<a href='/topic/show?id=693f4185542' target=_blank style='color:#2F92EE;'>#基因组计划#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=41855, encryptionId=693f4185542, topicName=基因组计划)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=bf1b289, createdName=villahu, createdTime=Sat Apr 30 05:16:00 CST 2016, time=2016-04-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1467101, encodeId=8894146e10162, content=<a href='/topic/show?id=ef32e9539e8' target=_blank style='color:#2F92EE;'>#罕见#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79539, encryptionId=ef32e9539e8, topicName=罕见)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=29f36868190, createdName=syscxl, createdTime=Wed Sep 23 02:16:00 CST 2015, time=2015-09-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=37121, encodeId=6f353e121f6, content=不错的视角,长见识了, beContent=null, objectType=article, channel=null, level=null, likeNumber=119, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e73d1605484, createdName=he408015781, createdTime=Mon Sep 21 21:19:00 CST 2015, time=2015-09-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=37122, encodeId=9c143e122ef, content=不错的视角,长见识了, beContent=null, objectType=article, channel=null, level=null, likeNumber=158, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e73d1605484, createdName=he408015781, createdTime=Mon Sep 21 21:19:00 CST 2015, time=2015-09-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=37123, encodeId=13f23e123da, content=不错的视角,长见识了, beContent=null, objectType=article, channel=null, level=null, likeNumber=105, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e73d1605484, createdName=he408015781, createdTime=Mon Sep 21 21:19:00 CST 2015, time=2015-09-21, status=1, ipAttribution=)]
    2015-09-21 he408015781

    不错的视角,长见识了

    0

相关资讯

罕见病:改变从了解开始

编者按:有多少人还记得去年夏天狂欢风靡的冰桶挑战,又有多少人还记得这些需要帮助的罕见病患者。正如罕见病发展中心主任黄如方所言,我们做的还远远不够。生物谷也尽一己之力,呼吁发起更多的学者关注罕见病,借助2015中国人类罕见病的基础和转化医学高峰论坛推动罕见病研究,提高诊治水平,并希望以此为契机,促进社会对罕见病患者的关爱,推动相关法律政策的制定原标题 《新年寄语:新的一年,不说快乐说加油》当中国

罕见病救助:“青岛模式”带给我们的思考与启示

引言:去年盛夏,"冰桶挑战"的火热,让"罕见病"这个在国内还不被大众所了解的领域,在近一年时间内频频进入公众视野。据国内医学界估算,在我国有超过1600多万的各类罕见病患者,这是一个不可忽视的庞大社会群体。随着国内经济、文化的快速发展,居民对生活质量的追求,对健康的期望,对享有医疗保障的需要,已越来越高。罕见病领域所面临的问题,已成了国家精神文明建设,创建社会和谐家园,实现伟大"中国梦"征途上

不孤独的孤儿药(下篇):孤独在中国

和欧美孤儿药研发火爆现状截然不同,目前我国的孤儿药研发和欧美相比实在是冰火两重天,中国本土自主研发成功的孤儿药微乎其微,深圳微芯的西达苯胺算是一个罕见的亮点,今年年初获批上市的首个适应症是复发及难治性外周T细胞淋巴瘤,是中国首个授权美国等发达国家专利使用的原创新药。由于像西达苯胺这样用于治疗罕见病的中国本土孤儿药比罕见病本身要罕见的多,所以中国患者和家属只能期待国外药品公司在中国尽快获得罕

JAMA:罕见病诊断的新思路

罕见病的诊断和治疗一直都是难题,而测序技术的出现则带来了一丝曙光。一般来说,患者出现一些症状后,通常先看医生,然后开展外显子组测序,并借助研究人员,找到分子机制。然而,根据《美国医学会杂志》(JAMA)上的一篇文章,这个顺序现在反过来了。文章讲述了一个荷兰男孩的故事。他叫Vincent Pieterse,出生在2002年底。在婴儿时期,他似乎很健康,不过随着他渐渐长大,出现了学习障碍、轻微自闭症、

我国罕见病治疗诊断现状

不久前风靡一时的"挑战冰桶",让社会大众开始逐渐关注到了渐冻人、瓷娃娃等罕见病群体。罕见病是指那些患病率较低的疾病,又称"孤儿病"。 根据世界卫生组织(WHO)的定义,罕见病为患病人数占总人口的0.65‰~1‰的疾病。世界各国根据自己国家的具体情况,对罕见病的认定标准存在一定的差异。例如,美国将罕见病定义为每年患病人数少于20万人(或发病人口比例小于1/1500)的疾病;日本规定,罕见病为患病

2014年FDA批准的罕见病药物大回顾

欧洲罕见病组织(EURODIS)在2008年将每年2月最后一天定为“国际罕见病日”(Rare Disease Day),其宗旨在于唤起大众对罕见病患的重视。依据欧盟的定义,罕见病是每2000人中仅有1人会得且无法医治的疾病。目前罕见病的种类已超过7000种,其中80%的罕见病是由基因引发。2015年2月28日是第八个国际罕见病日,历届罕见病日都有一个主题。 第一界,2008年2月29日,呼吁社会